Hengrui Pharmaceutical announced that its subsidiaries Suzhou Shengdia Biomedical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. have recently received the “Drug Clinical Trial Approval Notice” for injectable Ruikang trastuzumab and adbelizumab injections approved and issued by the State Drug Administration, and will conduct clinical trials in the near future. Among them, injectable recontrastuzumab combined with PD-1/PD-L1 inhibitors were clinically tested in perioperative patients with resectable non-squamous non-small cell lung cancer with HER2 abnormalities.

Hengrui Pharmaceutical announced that its subsidiaries Suzhou Shengdia Biomedical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. have recently received the “Drug Clinical Trial Approval Notice” for injectable Ruikang trastuzumab and adbelizumab injections approved and issued by the State Drug Administration, and will conduct clinical trials in the near future. Among them, injectable recontrastuzumab combined with PD-1/PD-L1 inhibitors were clinically tested in perioperative patients with resectable non-squamous non-small cell lung cancer with HER2 abnormalities.